未登录

L

Lidia Sambucetti

sri international

H指数:23

被引数:4,175

浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-10-010

PRE

Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

PRE

Mega-High-Throughput Screening Platform for the Discovery of Biologically Relevant Sequence-Defined Non-Natural Polymers

ACS CENTRAL SCIENCE

IF10.4

2022-01-114

OAAI

Primary tumor data analysis reveals novel synthetic lethal dependencies between KRAS mutation and the spliceosome

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-12-010

PRE

Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Synthetic lethality-based predictive biomarker identification of splicing modulators in lung cancer

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Assessing the therapeutic efficacy of disease-specific T-cell biofactories

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Primary tumor data mining identifies a novel synthetic lethal partner of the BRCA1 mutation in breast cancer

CANCER RESEARCH

IF16.6

2018-07-010

PRE

New cancer prevention model using imaging for early detection of mesothelin-expressing cancers

CANCER RESEARCH

IF16.6

2017-07-010

PRE

A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor scaffold

CANCER RESEARCH

IF16.6

2017-07-010

PRE

A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2016-12-1240

OAAI

MAP4K4 as a therapeutic target and novel biomarker for NSCLC

CANCER RESEARCH

IF16.6

2016-07-150

PRE

A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy

JOURNAL OF VIROLOGY

IF3.8

2016-03-0164

OAAI

Targeting the SF3B1 spliceosome protein: Development of a reporter for HTS screen and pharmacodynamic profiling of small molecule drug leads

CANCER RESEARCH

IF16.6

2015-08-010

PRE

SRI-28731, a highly potent and selective MAP4K4 (HGK) inhibitor for cancer therapy

CANCER RESEARCH

IF16.6

2014-10-010

PRE

In vivo animal models with patient-derived tumor xenografts for better clinical prediction

CANCER RESEARCH

IF16.6

2014-10-010

PRE

5′-AMP-activated Protein Kinase (AMPK) Supports the Growth of Aggressive Experimental Human Breast Cancer Tumors

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2014-08-0161

OAAI

Using Fiber Array Scanning Technology (FAST) Platform for sensitive detection and analysis of circulating tumor cells with a hybrid epithelial/mesenchymal phenotype from non-small cell lung cancer.

MOLECULAR CANCER THERAPEUTICS

IF5.5

2013-11-010

PRE

Antitumor activity of SR16388 on multiple myeloma targets factors needed for adaptation to bone marrow microenvironment

CANCER RESEARCH

IF16.6

2011-04-010

PRE

SR13668, a selective 12-lipoxygenase inhibitor, suppresses tumor growth by modulating the Akt signaling pathway

CANCER RESEARCH

IF16.6

2011-04-010

PRE